Disease Landscape and Forecast Insights

The multiple myeloma therapy market continues to grow, fueled by the disease’s increasing incidence and long treatment durations. The availability of premium-priced branded agents prescribed in…

CAR T-cell therapies have given new hope to patients with relapsed/refractory (R/R) non-Hodgkin’s lymphoma (NHL) and more recently to patients with R/R multiple myeloma. Priced at more than $350,…

Multiple myeloma remains an incurable hematological malignancy despite the availability of several treatments. Resistance to therapy is the primary challenge associated with the disease’s relapse…

The approval two CAR T-cell therapies for relapsed / refractory B-cell hematological malignancies—Novatis’ Kymriah for acute lymphoblastic leukemia (ALL) and large B-cell lymphoma and Kite…

Chemotherapy has formed the backbone of oncology treatment for decades, and it continues to remain a critical cornerstone of antineoplastic drug therapy. The chemotherapy market is heavily…

The availability of premium-priced branded agents prescribed in doublet, triplet, and quadruplet regimens, particularly Darzalex-based therapies, has had an impressive impact on the treatment of…

MARKET OUTLOOK Multiple myeloma is an incurable hematological malignancy with a 100% mortality rate that affects a sizeable Chinese population every year. With the introduction of proteasome…

Market Outlook The multiple myeloma landscape is witnessing successive label expansions. The availability of premium-priced branded agents prescribed in not just doublet and triplet regimens but…

MARKET OUTLOOKSuccessive label expansions in the multiple myeloma treatment landscape are driving significant commercial reward for some well-entrenched current therapies. With Celgene’s Revlimid…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to…